AndreaBozzo/ceres-open-data-index huggingface dataset:
Health Plan Prior Authorization Data

In 2020, the Washington State Legislature enacted Engrossed Substitute Senate Bill (ESSB) 6404 (Chapter 316, Laws of 2020, codified at RCW 48.43.0161), which requires that health carriers with at least one percent of the market share in Washington State annually report certain aggregated and de-identified data related to prior authorization to the Office of the Insurance Commissioner (OIC). Prior authorization is a utilization review tool used by carriers to review the medical necessity of requested health care services for specific health plan enrollees. Carriers choose the services that are subject to prior authorization review. The reported data includes prior authorization information for the following categories of health services:<br>
•	Inpatient medical/surgical <br>
•	Outpatient medical/surgical <br>
•	Inpatient mental health and substance use disorder <br>
•	Outpatient mental health and substance use disorder <br>
•	Diabetes supplies and equipment <br>
•	Durable medical equipment <br><br>

The carriers must report the following information for the prior plan year (PY) for their individual and group health plans for each category of services:<br>
•	The 10 codes with the highest number of prior authorization requests and the percent of approved requests.<br>
•	The 10 codes with the highest percentage of approved prior authorization requests and the total number of requests.<br>
•	The 10 codes with the highest percentage of prior authorization requests that were initially denied and then approved on appeal and the total number of such requests. <br><br>

Carriers also must include the average response time in hours for prior authorization requests and the number of requests for each covered service in the lists above for:<br>
•	Expedited decisions. <br>
•	Standard decisions. <br>
•	Extenuating-circumstances decisions.<br><br>

Engrossed Second Substitute House Bill 1357 added additional prescription drug prior authorization reporting requirements for health carriers beginning in reporting year 2024. Carriers were provided the opportunity to submit voluntary prescription drug prior authorization data for the 2023 reporting period. Prescription drug reporting was required for the 2024 reporting period.
Measurement of tracheal temperature is not a reliable index of total respiratory heat loss in mechanically ventilated patients

Background:
          Minimizing total respiratory heat loss is an important goal during mechanical ventilation. The aim of the present study was to evaluate whether changes in tracheal temperature (a clinical parameter that is easy to measure) are reliable indices of total respiratory heat loss in mechanically ventilated patients.
        
        
          Method:
          Total respiratory heat loss was measured, with three different methods of inspired gas conditioning, in 10 sedated patients. The study was randomized and of a crossover design. Each patient was ventilated for three consecutive 24-h periods with a heated humidifier (HH), a hydrophobic heat-moisture exchanger (HME) and a hygroscopic HME. Total respiratory heat loss and tracheal temperature were simultaneously obtained in each patient. Measurements were obtained during each 24-h study period after 45 min, and 6 and 24 h.
        
        
          Results:
          Total respiratory heat loss varied from 51 to 52 cal/min with the HH, from 100 to 108 cal/min with the hydrophobic HME, and from 92 to 102 cal/min with the hygroscopic HME (P < 0.01). Simultaneous measurements of maximal tracheal temperatures revealed no significant differences between the HH (35.7-35.9°C) and either HME (hydrophobic 35.3-35.4°C, hygroscopic 36.2-36.3°C).
        
        
          Conclusion:
          In intensive care unit (ICU) mechanically ventilated patients, total respiratory heat loss was twice as much with either hydrophobic or hydroscopic HME than with the HH. This suggests that a much greater amount of heat was extracted from the respiratory tract by the HMEs than by the HH. Tracheal temperature, although simple to measure in ICU patients, does not appear to be a reliable estimate of total respiratory heat loss.
CDPHE Colorado Drug Treatment Programs and Resources

Point geometry feature class representing known Colorado Drug Treatment Program Resource locations (Methadone Clinics and Narcotic Addiction Treatment Programs), developed directly from address information obtained directly from the Office of Emergency Preparedness and Response, Colorado Department of Public Health and Environment, in 2017.  Coordinate locations (latitude/longitude) were derived from the known street addresses of health facilities using a combination of Centrus MapMarker geocoding software and Google Earth imagery locations.  This file was developed for use in activities and exercises within the Colorado Department of Public Health and Environment.
Unique presentations and chronic complications in adult cystic fibrosis: do they teach us anything about CFTR?

The increase in numbers of adults with cystic fibrosis (CF) has allowed us to identify previously unrecognized chronic complications of CF, as well as appreciate unique presentations of cystic fibrosis-related diseases. Do these chronic complications and unique presentations provide us with new insight into cystic fibrosis transmembrane conductance regulator (CFTR) function? Current data suggest that the 'chronic complications' reveal mainly the effect of a long-term absence of previously recognized CFTR functions. In contrast, the 'unique presentations' provide new insight into the role of CFTR in different tissues.
Direct microscopic examination of imprints in patients undergoing cardiac valve replacement

Background
          Bacteriological analysis of cardiac valves might be indicated in patients with suspected endocarditis.
        
        
          Methods
          We report here a prospective study on fifty-three consecutive patients whose native valves were sent to the bacteriological and pathological laboratories, to investigate the performance of direct microscopic examination of imprints and valve culture.
        
        
          Results
          On the basis of a histopathological gold standard to classify the inflammatory valve process, the sensitivity, the specificity, the positive and the negative predictive values of direct microscopic examination of imprints and valve culture were 21%, 100%, 100%, 60%, and 21%, 72%, 38%, 52% respectively. This weak threshold of the direct microscopic examination of imprints could be due to antimicrobial therapy prescribed before cardiac surgery and the fact that the patients came from a tertiary hospital receiving patients with a prolonged history of endocarditis.
        
        
          Conclusion
          Clinical context and histopathology are indispensable when analyzing the imprints and valve culture.
MD iMAP: Maryland Community Health Resource Commission - Safety Net Capacity Building Grantees

This is a MD iMAP hosted service. Find more information at  http://imap.maryland.gov. Safety Net Capacity Building Grantees - The Maryland Community Health Resources Commission works to expand access to health care services for low-income and under-served communities across the state.Feature Service Link:http://geodata.md.gov/imap/rest/services/Health/MD_CommunityHealthResourceCommission/FeatureServer/7 ADDITIONAL LICENSE TERMS: The Spatial Data and the information therein (collectively "the Data") is provided "as is" without warranty of any kind either expressed implied or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct indirect incidental consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
A Day in the Life of Older Adults: Substance Use Facts

This report presents facts about substance use among adults age 65 and older, including information on substance use on an average day, receipt of substance use treatment, and emergency department (ED) visits. This paper draws upon three SAMHSA data collections: the National Survey on Drug Use and Health (NSDUH), the Treatment Episode Data Set (TEDS), and the Drug Abuse Warning Network (DAWN).
Public Health Statistics - Asthma hospitalizations in Chicago, by year, 2000-2011 - Historical

Note: This dataset is historical only and there are not corresponding datasets for more recent time periods. For that more-recent information, please visit the Chicago Health Atlas at https://chicagohealthatlas.org.

This dataset contains the annual number of hospital discharges, crude hospitalization rates with corresponding 95% confidence intervals, and age-adjusted hospitalization rates (per 10,000 children and adults aged 5 to 64 years) with corresponding 95% confidence intervals, for the years 2000 – 2011, by Chicago U.S. Postal Service ZIP code or ZIP code aggregate. See the full dataset description for more information at http://bit.ly/PKI8p0.
2014 CMHS Uniform Reporting System (URS) Table for Wisconsin

2014 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Wisconsin. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Patent AT-E40032-T1: [Translated] BUCKLE WITH RETENTION DEVICES FOR DECORATIVE ELEMENTS.

A buckle (10) comprising a decorative outer frame (11) having a circumferential top wall (12) and opposed depending side walls extending rearwardly of the top wall (12). A channel (15) is defined between the depending side walls under the top wall (12). A casted back member is provided with a projection portion which is configured to be received in the channel (15). The outer frame is retained on the casted back member by bending the outer one of the side walls under the projection portion which is received at least in part in the channel (15). The casted back may have a variety of designs and attachments all formed in a single casting.
Compound 528901: Hexobarbital M (OH,-H2O)

Chemical compound data from PubChem database. IUPAC Name: 5-cyclohexa-1,3-dien-1-yl-5-methyl-1,3-diazinane-2,4,6-trione. Molecular Formula: C11H12N2O3. Molecular Weight: 220.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528564: alpha-Resorcylic acid, TBDMS

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 3,5-bis[[tert-butyl(dimethyl)silyl]oxy]benzoate. Molecular Formula: C25H48O4Si3. Molecular Weight: 496.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Table 1. 2011-2012 NSDUH Illicit Drug Use in the Past Month, by Age Group and State

Table 1. Illicit Drug Use in the Past Month, by Age Group and State: Percentages, Annual Averages Based on 2011 and 2012 NSDUHs.  Results are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
National Directory of Drug and Alcohol Abuse Treatment Facilities - 1982

The National Directory of Drug and Alcohol Abuse Treatment Programs 1982 lists federal, state, local, and private facilities that provide substance abuse treatment services. The directory includes treatment facilities that are licensed, certified, or otherwise approved for inclusion in the directory by their state substance abuse agencies and that responded to the 1982 National Survey of Substance Abuse Treatment Services (N-SSATS). The information about each facility that appears in this directory was provided by that facility in response to the 1981 N-SSATS. The Substance Abuse and Mental Health Services Administration (SAMHSA) conducts the N-SSATS annually.
Compound 529343: Pyridine, 2,4-bis-(1-methylethyl)

Chemical compound data from PubChem database. IUPAC Name: 2,4-di(propan-2-yl)pyridine. Molecular Formula: C11H17N. Molecular Weight: 163.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2010 State Profile — Palau

This state profile includes data from facilities in Palau that reported to N-SSATS for the survey reference date March 31, 2010. Data were collected on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (both public and private) in Palau. In Palau, 1 substance abuse treatment facility was included in the 2010 N-SSATS, reporting that there were 104 clients in substance abuse treatment on March 31, 2010. The survey response rate in Palau was 100.0%.
NNDSS - Table II. Babesiosis to Campylobacteriosis

NNDSS - Table II. Babesiosis to Campylobacteriosis - 2017. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data.  Data on United States exclude counts from US territories.

Note:
These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. 

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. 

Footnotes:
 C.N.M.I.: Commonwealth of Northern Mariana Islands. 

U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. 

* Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.
 
† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.
RadLex

<p>RadLex is a controlled terminology for radiology and serves as a single unified source of radiology terms for radiology practice, education, and research. RadLex is a comprehensive lexicon for standardized indexing and retrieval of radiology information resources. With more than 30,000 terms, RadLex satisfies the needs of software developers, system vendors and radiology users by adopting the best features of existing terminology systems while producing new terms to fill critical gaps. RadLex also provides a comprehensive and technology-friendly replacement for the ACR Index for Radiological Diagnoses. It unifies and supplements other lexicons and standards, such as SNOMED-CT, LOINC, and DICOM. As images, image reports, and medical records continue to move online RadLex meets the need of physicians to organize and retrieve image data using a common set of terms.&#13;<br />
&#13;<br />
RadReport is a radiology reporting initiative that is a part of RadLex. RadReport aims to improve reporting practices by creating a library of clear and consistent report templates.  Report templates and information about RadReport is available at the link in Resource 2.&#13;<br />
&#13;</p>
Treatment Episode Data Set (TEDS): 2004-2014, State Admissions To Substance Abuse Treatment Services

This report uses data from the Treatment Episode Data Set (TEDS) to examine treatment admission data in 2014, and trend data from 2004 to 2014, nationally, regionally (by the four Census regions and the nine Census divisions), and by state or jurisdiction. The report provides information on the demographic and substance abuse characteristics of admissions to treatment aged 12 and older for abuse of alcohol and/or drugs in facilities that report to individual state administrative data systems. It is important to note that values in charts, narrative lists, and percentage distributions are calculated using actual raw numbers and rounded for presentation in this report; calculations using rounded values may produce different results. For 2014, a total of 1,614,358 admissions aged 12 and older were reported to TEDS by 49 states, the District of Columbia, and Puerto Rico (South Carolina, which is in the South Atlantic Census division, did not report sufficient admissions for 2014)
Compound 528950: Phenol, 2-(1-ethylpropyl)-4-nitro

Chemical compound data from PubChem database. IUPAC Name: 4-nitro-2-pentan-3-ylphenol. Molecular Formula: C11H15NO3. Molecular Weight: 209.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Program Instruction (PI-11-08)

This Program Instruction (PI) provides information to States and Tribes concerning changes regarding the APD waiver process within the Federal regulations at 45 CFR 95, and offers guidance when requesting a waiver to use a commercial-off-the-shelf (COTS) software product designed for the Title IV-E or Title IV-B programs.

Metadata-only record linking to the original dataset. Open original dataset below.
Cladribine

Cladribine is a prescription injectable medication used as a chemotherapy drug to treat certain blood cancers, such as hairy cell leukemia. It works as a purine antimetabolite to interfere with cancer cell growth. Manufactured by Fresenius Kabi USA, LLC, it's administered intravenously at a strength of 1 mg/mL in single-dose vials. Approved under ANDA076571 since 2004. This information was generated using AI and is provided for informational and research purposes only.
Patent AT-E40159-T1: [Translated] PROCESS FOR PREPARING BOTH POLYOLEFIN GEL ARTICLES AND MAKING ARTICLES WITH HIGH TENSILE STRENGTH AND ELASTIC MODULE.

Highly stretchable gel articles are prepared by contacting a shaped solvent-containing or solvent-free article of a high molecular weight polyolefin with a gaseous or liquid swelling agent at elevated temperature untill the swollen article contains 60-99 % (wt) of swelling agent, and cooling this article below the gelling temperature. The gel articles can be transformed into articles (filaments, tapes, films, tubes, bars) of high strength and modulus, by stretching at elevated temperature.
Compound 529299: Hexanoic acid, 5-(acetyloxy)-, ethyl ester

Chemical compound data from PubChem database. IUPAC Name: ethyl 5-acetyloxyhexanoate. Molecular Formula: C10H18O4. Molecular Weight: 202.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527988: Pentanoic acid, 2-chloro-1-(chloromethyl)ethyl ester

Chemical compound data from PubChem database. IUPAC Name: 1,3-dichloropropan-2-yl pentanoate. Molecular Formula: C8H14Cl2O2. Molecular Weight: 213.1. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Managed Care Institutional Provider Network Data: June 30, 2015

The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of Managed Care plans in New York State, including HIV Special Need Plans (SNP), Family Health Plus (FHP) Buy-In, Programs of All-Inclusive Care for the Elderly (PACE), and Non-PACE Managed Long-Term Care (MLTC) plans. This dataset reflects institutional provider data. Provider Network Data System information is self reported. For more information, go to http://www.health.ny.gov/health_care/managed_care/.
Compound 528428: Flavanone, 5,7-dihydroxy, bis-TMS

Chemical compound data from PubChem database. IUPAC Name: 2-phenyl-5,7-bis(trimethylsilyloxy)-2,3-dihydrochromen-4-one. Molecular Formula: C21H28O4Si2. Molecular Weight: 400.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530120: 5-Methoxytryptophol, TMS

Chemical compound data from PubChem database. IUPAC Name: 2-(5-methoxy-1-trimethylsilylindol-3-yl)ethoxy-trimethylsilane. Molecular Formula: C17H29NO2Si2. Molecular Weight: 335.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
4.17b Facilities employing specific practices as part of their standard operating procedures, by facility operation and primary focus of facility: 2011. Percent

This is a National Survey of Substance Abuse Treatment Services (N-SSATS) data table showing facilities employing specific practices as part of their standard operating procedures, by facility operation and primary focus of facility in 2011. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.
Compound 526373: 1,2,6,9-Tetrabromo-dibenzo-dioxin

Chemical compound data from PubChem database. IUPAC Name: 1,2,6,9-tetrabromodibenzo-p-dioxin. Molecular Formula: C12H4Br4O2. Molecular Weight: 499.77. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530689: 4-Ethylbenzoic acid, tridec-2-ynyl ester

Chemical compound data from PubChem database. IUPAC Name: tridec-2-ynyl 4-ethylbenzoate. Molecular Formula: C22H32O2. Molecular Weight: 328.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Eletriptan hydrobromide

Eletriptan Hydrobromide is a generic prescription medication used to treat migraine headaches. It comes as oral tablets in 20 mg and 40 mg strengths, manufactured by Aurobindo Pharma Limited. As a serotonin receptor agonist, it helps relieve migraine symptoms by narrowing blood vessels in the brain. This information was generated using AI and is provided for informational and research purposes only.